The 5 linked references in paper M. Frolov Yu., V. Rogov A., М. Фролов Ю., В. Рогов А. (2016) “Фармакоэкономическое обоснование применения препарата Ленвима® (ленватиниб) при прогрессирующем дифференцированном раке щитовидной железы, рефрактерном к радиоактивному йоду, в Российской Федерации // PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION” / spz:neicon:pharmacoeconomics:y:2016:i:1:p:24-32

  1. Cabanillas M.E., Habra M.A. Lenvatinib: Role in thyroid cancer and other solid tumors. Cancer Treat Rev. 2016 Jan; 42: 47-55. DOI: 10.1016 - j.ctrv.2015.11.003. Epub 2015 Dec 2.
  2. Fordham B.A., Kerr C.L., de Freitas H.M. et al. Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer. Patient Prefer Adherence. 2015 Nov 3; 9: 1561-1572. DOI: 10.2147/PPA.S90425.
  3. Frampton J.E. Lenvatinib: A Review in Refractory Thyroid Cancer. Target Oncol. 2016 Feb; 11 (1): 115-22. DOI: 10.1007/s11523015-0416-3.
  4. World Health Organization. Who choice Unit Costs Database. http://www.who.int/choice/costs/en/. Accessed: 12.01.16.
  5. Yeung K.T., Cohen E.E. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma. Clin Cancer Res. 2015 Dec 15; 21 (24): 5420-5426. DOI: 10.1158/1078-0432. CCR-15-0923.